Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

1.330 -0.040 (-2.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cardiol Therapeutics Inc. - Class A Common Shares

< Previous 1 2 3 4 Next >
News headline image
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Via Get News
Topics Intellectual Property
News headline image
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Via Get News
Topics Intellectual Property
News headline image
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Via Get News
Topics Intellectual Property
News headline image
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today ↗
Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering. 
Via Benzinga
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and 
Via PressReach
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac... 
Via Newsfile
News headline image
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
(August 6, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory 
Via PressReach
News headline image
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by... 
Via Newsfile
News headline image
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options
Via Investor Brand Network
News headline image
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart
Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... 
Via Newsfile
News headline image
“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”
Via AB Newswire
News headline image
3 Penny Stocks Ready to Break Out in 2025
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products. 
Via MarketBeat
News headline image
Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!
Via AB Newswire
News headline image
“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
Via AB Newswire
Topics Economy
News headline image
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
Via AB Newswire
News headline image
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study ↗
 
Via Benzinga
News headline image
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Via AB Newswire
News headline image
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially... 
Via Newsfile
News headline image
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
Via AB Newswire
Topics Electric Vehicles
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
Via AB Newswire
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
Via AB Newswire
Topics Government
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Via AB Newswire
Topics Intellectual Property
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
Via AB Newswire
News headline image
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday ↗
 
Via Benzinga
“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”
Via AB Newswire
News headline image
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024 ↗
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
Via TheNewswire.com
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.